TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05331859
Drug: autologous serum (AS)
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
Study: NCT05331859
Drug: conventional
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
Study: NCT05935826
Drug: Essential Amino Acid Supplement by Amino Co
Normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
Study: NCT05767879
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated.
Study: NCT05518318
Drug: GLS-010
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
Study: NCT05303844
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT05925478
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Study: NCT04698018
Drug: Faster Aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
Study: NCT04698018
Drug: Novo Rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
Study: NCT05145218
Drug: Anlotinib Hydrochloride Capsules
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Study: NCT05145218
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is a novel anti-microtubule agent.
Study: NCT00000679
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000679
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001113
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001113
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001113
Drug: Interferon alfa-n1
Normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04720976
Drug: JAB-3312
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAB-3312 will be administered orally, variable dose.
Study: NCT04720976
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib will be administered orally.
Study: NCT04720313
Drug: NXC-201 (formerly HBI0101)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
Study: NCT04720976
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as an intravenous infusion.
Study: NCT04720976
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib will be administered orally.
Study: NCT04720976
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib will be administered orally.
Study: NCT05219513
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
Study: NCT05219513
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
Study: NCT05219513
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Study: NCT06348134
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A chemotherapy drug.
Study: NCT06475105
Drug: Oral Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Study: NCT06348134
Drug: Pertuzumab Injection
Normalized name: pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Study: NCT06348134
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A chemotherapy drug.
Study: NCT06348134
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication used to treat breast cancer.
Study: NCT06348134
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication used to treat breast cancer.
Study: NCT06348134
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A hormone therapy drug.
Study: NCT04738942
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab 300 mg, IV infusion
Study: NCT05339685
Drug: BL-M02D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05401032
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral medication, once a day for 6 months.
Study: NCT05715723
Drug: Reamberin
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin® in the average daily dose of 10 ml/kg daily
Study: NCT05546580
Drug: Iadademstat
Normalized name: Iadademstat
DrugBank: ORY-1001 (DB16848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iadademstat oral solution
Study: NCT05546580
Drug: Gilteritinib Oral Tablet
Normalized name: gilteritinib Oral Tablet
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 120 mg Gilteritinib
Study: NCT06021600
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO and Given by IV (vein)
Study: NCT06280391
Drug: Itepekimab (SAR440340)
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
Study: NCT05795361
Drug: Idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
Study: NCT05042128
Drug: LSTA1
Normalized name: LSTA1
DrugBank: LSTA1 (DB17346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Study: NCT05042128
Drug: Gemcitabine Injection
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study: NCT05042128
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study: NCT06297772
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: decitabine 20mg/m2 per day for consecutive 5 days
Study: NCT06297772
Drug: Fludarabine Injection
Normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30mg/m2 per day for consecutive 5 days
Study: NCT06297772
Drug: Busulfan Injection
Normalized name: busulfan Injection
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 3.2mg/kg per day for consecutive 4 days
Study: NCT04119830
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05800600
Drug: Venofer
Normalized name: Venofer
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Study: NCT06022250
Drug: JS207
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive specific dose of JS207 via intravenous infusion.
Study: NCT06097975
Drug: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
Study: NCT06097975
Drug: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
Study: NCT05743244
Drug: Abrocitinib 200 MG Oral Tablet
Normalized name: abrocitinib 200 MG Oral Tablet
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abrocitinib
Study: NCT05743244
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib
Study: NCT06653738
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily per os for 3 years
Study: NCT05046327
Drug: Avatrombopag 20 mg Oral Tablet
Normalized name: avatrombopag 20 MG Oral Tablet
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
Study: NCT05783557
Drug: Clevidipine Butyrate Injectable Emulsion
Normalized name: Clevidipine Butyrate
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03935451
Drug: Apixaban 2.5 milligram
Normalized name: Product containing precisely apixaban 2.5 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
Study: NCT06494111
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06494111
Drug: Tocopherol
Normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06651892
Drug: Enema Phosphates Sodium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
Study: NCT05529095
Drug: Apomorphine Sublingual Film
Normalized name: apomorphine Sublingual Film
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
Study: NCT05795140
Drug: Iptcaopan 200 mg
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label, participant specific kits, hard gelatin capsules to be taken twice a day
Study: NCT06374043
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT06003283
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV rituximab
Study: NCT04494412
Drug: Zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
Study: NCT06518434
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical cannabis oil three times daily
Study: NCT05938712
Drug: Dapagliflozin 10 MG
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide subcutaneous once weekly for 12 weeks.
Study: NCT05938712
Drug: Semaglutide, 1.0 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin oral once daily for 12 weeks.
Study: NCT06226857
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles
Study: NCT00034593
Drug: ALIMTA
Normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034593
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05419635
Drug: Asundexian (BAY2433334)
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study intervention BAY2433334 will be administered as tablet taken orally.
Study: NCT05354453
Drug: BI 1839100
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1839100
Study: NCT05523401
Drug: 4-bromo-2,5-dimethoxyphenethylamine (10 mg)
DrugBank: 4-Bromo-2,5-dimethoxyphenethylamine (DB01537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A low dose of 10 mg 2C-B will be administered.
Study: NCT05523401
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 125 mg MDMA will be administered.
Study: NCT05523401
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 25 mg psilocybin will be administered.
Study: NCT05354453
Drug: allyl isothiocyanate (AITC)
Normalized name: benzophenone-4-isothiocyanate
DrugBank: Benzophenone (DB01878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: allyl isothiocyanate (AITC)
Study: NCT05734560
Drug: D2C7-IT
Normalized name: D2C7-IT
DrugBank: D2C7 immunotoxin (DB17540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2C7-IT will be dosed at 166,075 ng in 36 mL.
Study: NCT05945368
Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days
Study: NCT05186974
Drug: Sacituzumab Govitecan-hziy (SG)
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05186974
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05186974
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05186974
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05148195
Drug: Envofolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
Study: NCT05148195
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2，Q3W
Study: NCT05148195
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2，Q2W
Study: NCT06055959
Drug: Zilucoplan
Normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan will be administered subcutaneously to pediatric study participants.
Study: NCT05148195
Drug: 5-Fluorouridine
Normalized name: 2'-Deoxy-5-fluorouridine
DrugBank: 5-fluorouridine (DB01629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/m2，Q2W
Study: NCT05050279
Drug: Delgocitinib capsule
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral capsule
Study: NCT05219487
Drug: Risdiplam
Normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)
Study: NCT05186415
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Normalized name: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
Study: NCT06455605
Drug: D2C7-IT
Normalized name: D2C7-IT
DrugBank: D2C7 immunotoxin (DB17540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2C7-IT will be dosed at 166,075 ng in 36 mL.
Study: NCT00001068
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04645719
Drug: Magnesium sulfate dose through real weight group
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight
Study: NCT04645719
Drug: Magnesium sulfate dose through corrected ideal weight group
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
Study: NCT04714710
Drug: IV Potassium Canrenoate
Normalized name: canrenoate potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room